Compare GERN & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GERN | TRIN |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | 229 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | GERN | TRIN |
|---|---|---|
| Price | $1.58 | $14.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.17 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 16.9M | 1.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 14.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | $29.43 |
| Revenue Next Year | $43.75 | $6.80 |
| P/E Ratio | ★ N/A | $7.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $12.97 |
| 52 Week High | $2.01 | $17.20 |
| Indicator | GERN | TRIN |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 43.87 |
| Support Level | $1.24 | $14.35 |
| Resistance Level | $1.70 | $15.28 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 57.81 | 52.84 |
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.